-+ 0.00%
-+ 0.00%
-+ 0.00%

EMA validates PolyPid D-PLEX100 marketing authorization application, triggers formal review

PUBT·10/01/2026 13:15:28
Listen to the news
EMA validates PolyPid D-PLEX100 marketing authorization application, triggers formal review
  • EMA validated PolyPid’s marketing authorization application for D-PLEX100, triggering a formal review for preventing post-abdominal surgery incisional infections.
  • D-PLEX100’s US NDA remains under FDA Priority Review with a Nov. 28, 2026 PDUFA goal date.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PolyPid Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010915PRIMZONEFULLFEED9837888) on October 01, 2026, and is solely responsible for the information contained therein.